Fig. 3From: Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicityKaplan-Meier analysis of intracranial progression-free survival (PFS) after single-fraction radiosurgery (sf-SRS, blue line) or multi-fraction SRS (mf-SRS, red line) in combination with ipilimumab or nivolumab. Patients receiving mf-SRS had significantly better intracranial PFS than those treated with sf-SRS (a); differences in PFS were seen in both ipilimumab and nivolumab groups (b)Back to article page